Revisiting Exome Data Identified Missed Splice Site Variant of the Asparagine Synthetase (ASNS) Gene

Abstract

Next-generation sequencing, such as whole-exome sequencing (WES), is increasingly used in the study of Mendelian disorders, yet many are reported as “negative.” Inappropriate variant annotation and filtering steps are reasons for missing the molecular diagnosis. Noncoding variants, including splicing mutations, are examples of variants that can be overlooked. Herein, we report a family of four affected newborns, and all presented with severe congenital microcephaly. Initial research WES analysis identified a damaging homozygous variant in NME1 gene as a possible cause of primary microcephaly phenotype in these patients. However, reanalysis of the exome data uncovered a biallelic splice site variant in asparagine synthetase gene which seems to be the possible cause of the phenotype in these patients. This study highlights the importance of revisiting the exome data and the issue of “negative” exome and the afterward approaches to identify and prove new candidate genes.

Keywords

whole-exome sequencing - candidate genes - microcephaly - ASNS - NME1

• References

• 1 Yang Y.. et al. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. N. Engl. J. Med 369: 1502-1511 2013;
• 2 Stavropoulos D.J.. et al. Whole-genome sequencing expands diagnostic utility and improves clinical management in paediatric medicine. npj Genomic Med 1: 15012 2016;
• 3 Monies D.. et al. Lessons Learned from Large-Scale, First-Tier Clinical Exome Sequencing in a Highly Consanguineous Population. Am. J. Hum. Genet 104: 1182-1201 2019;
• 4 Bruel A.L.. et al. Next-generation sequencing approaches and challenges in the diagnosis of developmental anomalies and intellectual disability. Clinical Genetics 98: 433-444 2020;
• 5 Anna A., Monika G.. Splicing mutations in human genetic disorders: examples, detection, and confirmation. J. Appl. Genet 59: 253-268 2018;
• 6 Fung J.L. F.. et al. A three-year follow-up study evaluating clinical utility of exome sequencing and diagnostic potential of reanalysis. npj Genomic Medicine 5;2020
• 7 Puts G.S., Leonard M.K., Pamidimukkala N.V., Snyder D.E., Kaetzel D.M.. Nuclear functions of NME proteins. Laboratory Investigation 98: 211-218 2018;
• 8 Georgescauld F., Song Y., Dautant A.. Structure, folding and stability of nucleoside diphosphate kinases. International Journal of Molecular Sciences 21: 1-17 2020;
• 9 Richards N.G. J., Kilberg M.S.. Asparagine synthetase chemotherapy. Annu. Rev. Biochem 75: 629-654 2006;
• 10 Fagerberg L.. et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol. Cell. Proteomics 13 397-406 2014;
• 11 Ruzzo E.K.. et al. Deficiency of Asparagine Synthetase Causes Congenital Microcephaly and a Progressive Form of Encephalopathy. Neuron 80 429-441 2013;
• 12 Khanna T., Hanna G., Sternberg M.J. E., David A.. Missense3D-DB web catalogue: an atom-based analysis and repository of 4M human protein-coding genetic variants. Hum. Genet 140: 805-812 2021;
• 13 Rodrigues C.H. M., Myung Y., Pires D.E. V., Ascher D.B.. mCSM-PPI2: predicting the effects of mutations on protein–protein interactions. Nucleic Acids Res 47: W338-W344 2019;
• 14 Bilitou A., Watson J., Gartner A., Ohnuma S.I.. The NM23 family in development. Molecular and Cellular Biochemistry 329: 17-33 2009;
• 15 Al-Nabhani M.. et al. Reanalysis of exome sequencing data of intellectual disability samples: Yields and benefits. Clin. Genet 94: 495-501 2018;
• 16 Alfares A.. et al. Whole-genome sequencing offers additional but limited clinical utility compared with reanalysis of whole-exome sequencing. Genet. Med 20: 1328-1333 2018;
• 17 Burdick K.J.. et al. Limitations of exome sequencing in detecting rare and undiagnosed diseases. Am. J. Med. Genet. Part A 182 1400-1406 2020;
• 18 Brogna S., Wen J.. Nonsense-mediated mRNA decay (NMD) mechanisms. Nat. Struct. Mol. Biol. 2009 162 (16) 107-113 2009;